Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Turkey Tail

Trametes versicolor · PSK · Yun Zhi

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The evidence splits sharply and the honest grade depends on which product you mean. The purified pharmaceutical extract PSK (Krestin, Kureha) earns roughly a 3, mixed-to-moderate leaning positive, as an ADJUNCT to surgery and chemotherapy in resected gastric and colorectal cancer. That grade rests on named Japanese randomized trials and pooled analyses: the SIP gastric study (Nakazato et al., Lancet 1994, 5-year survival 73.0 vs 60.0 percent, p=0.044), the Oba et al. gastric meta-analysis (hazard ratio 0.88, 95 percent CI 0.79 to 0.98, p=0.018), and colorectal work by Mitomi et al. (5-year survival 78.5 vs 69.7 percent, p=0.0325) and the Sakamoto et al. meta-analysis (overall-survival risk ratio 0.71, 95 percent CI 0.55 to 0.90, p=0.006). The caveats that hold it at 3 rather than 4 are real: nearly all positive trials were conducted in Japan, many are older and open-label, and blinding is inconsistent. For the OTC turkey-tail powder or capsule that a US shopper actually buys, the grade is far lower, closer to a 2, and only for immune modulation. The one federally funded US human trial (Torkelson et al. 2012) was a small Phase I safety study of 11 women that showed only non-significant immune trends, not a cancer outcome. OTC products are not standardized to PSK content and are not the drug studied in the oncology trials.

FDA
Approved cancer drug (Japan); supplement (US)
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Very well tolerated, mostly mild GI effects and benign nail or stool darkening; the real risk is confusing an unstandardized OTC powder for the studied pharmaceutical drug, and using it in cancer care without an oncologist.

Turkey tail is the fan-shaped polypore Trametes versicolor, known for centuries in Chinese medicine as yun zhi and in Japan as kawaratake. It holds an unusual place in the mushroom aisle because one purified fraction of it, protein-bound polysaccharide K, became an approved prescription cancer drug in Japan in the 1970s under the name Krestin. Japanese randomized trials and several meta-analyses associate PSK, added to surgery and chemotherapy, with modestly longer survival in resected gastric and colorectal cancer. The honest catch is that the powder or capsule sold over the counter in the US is not that drug. It is an unstandardized dietary supplement, its PSK content is unknown, and the human evidence for the retail product is thin, mostly a single small safety trial showing immune trends.

A real approved cancer drug in Japan, sold as a supplement in the US.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Adjuvant support alongside surgery and chemotherapy in resected gastric or colorectal cancer, as PSK, coordinated with an oncology team
  • General immune modulation
  • Post-illness or convalescent immune support (traditional use)
  • Investigational immune support during cancer care (OTC forms, weak evidence)

How it is supposed to work

Turkey tail (Trametes versicolor) contains two pharmaceutically characterized polysaccharide-protein complexes: PSK (Polysaccharide-K, Krestin) and PSP (Polysaccharopeptide). Both work through immune activation of macrophages, natural killer cells, and T-lymphocyte populations. PSK in particular has been characterized as a "biological response modifier", it does not directly kill cancer cells but enhances the host immune response when added to conventional chemotherapy. The mechanism is among the most rigorously characterized of any supplement-category compound.

How it is taken

Turkey tail is typically dosed at 1-3g daily of dual-extracted Trametes versicolor fruit body, or 500-1000mg 1-2 times daily of standardized extract concentrate. In Japan, the pharmaceutical PSK (Krestin) is dosed at 3g daily as adjunctive cancer therapy, the substantial clinical evidence framework supporting Japanese gastric and colorectal cancer adjuvant use established the pharmaceutical positioning. US supplement-grade turkey tail is not equivalent to PSK pharmaceutical standardization but provides reasonable supplement-grade framework for immune support applications. Take consistently, adaptogenic and immune modulation effects develop over weeks of consistent supplementation. The substantial form-factor preference is cultivated fruit body over mycelium-on-grain (substantially better active compound content). Dual extraction (hot water + ethanol) provides broadest pharmacological coverage. The substantial cancer adjuvant context positioning requires substantial oncology coordination, turkey tail is not substitute for established cancer therapy; reasonable adjunctive supplementation under oncology coordination based on Japanese pharmaceutical PSK clinical evidence. Take with or without food, absorption is reasonable either way. The drug interaction profile is modest at standard supplementation doses; immunosuppressant users warrant substantial specialist coordination given beta-glucan immune modulation potential, particularly concerning in transplant medicine contexts. Anticoagulant users warrant coordination given modest antiplatelet effects. Pregnancy and lactation: generally avoid given limited safety data; OB-GYN coordination if used. Pediatric use: specialist coordination given limited pediatric safety data. The Paul Stamets advocacy framework (Stamets' mother's breast cancer adjuvant use is foundational Stamets narrative) provides substantial brand context though clinical evidence translation requires substantial oncology framework.

Standard daily dose
1-3g cultivated fruit body daily
Dual-extract dose
500-1000mg 1-2x daily
Japan pharmaceutical PSK
3g daily adjunctive cancer therapy
Beta-glucan content
30-50% standardized
Form preference
Cultivated fruit body > mycelium-on-grain
Extraction preference
Dual extract > single extract > whole powder
Cancer adjuvant context
Oncology coordination essential
Take with
With or without food

Which form to buy

Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.

  • PSK (Polysaccharide-K / Krestin) Pharmaceutical Extract

    Rating: gold

    Pharmaceutical-grade PSK extracted from cultivated Trametes versicolor strain CM-101. Approved as adjunctive cancer therapy in Japan since 1977 (Sankyo / Daiichi Sankyo pharmaceutical product). Substantial clinical evidence inheritance from Japanese gastric/colorectal cancer adjuvant trials (Nakazato 1994 NEJM, Mitomi 1992 Lancet). Standardized 3g daily pharmaceutical dosing in Japan. Not available as pharmaceutical product in US/Europe; available through specialty sources.

  • PSP (Polysaccharopeptide) Chinese Pharmaceutical Extract

    Rating: gold

    Pharmaceutical-grade PSP from Trametes versicolor strain Cov-1 cultivated in China. Substantial clinical evidence from Chinese gastric/lung/esophageal cancer adjuvant trials. Different strain than PSK; comparable mechanism profile. Standardized pharmaceutical dosing varies by clinical application.

  • Standardized Turkey Tail Dual Extract (US Supplement)

    Rating: gold

    Dual extraction (hot water for beta-glucans + ethanol for triterpenes) of cultivated Trametes versicolor fruit body. US supplement-grade alternatives to PSK/PSP pharmaceutical products. Real Mushrooms, Host Defense, Aloha Medicinals, Oriveda, and similar reputable brands. Standardized to beta-glucan content (typically 30-50%); not equivalent to PSK pharmaceutical standardization but reasonable supplement-grade framework.

  • Whole Turkey Tail Fruit Body Powder

    Rating: good

    Whole dried fruit body powder of Trametes versicolor. Modest pharmacological coverage relative to standardized extracts; reasonable consumer framework for traditional supplementation.

  • Mycelium-on-Grain Turkey Tail

    Rating: caution

    Mycelium grown on rice or oats, substantially less expensive but contains substantial grain starch and substantially diluted active compound content versus fruit body. Reasonable budget option; substantially inferior to cultivated fruit body for therapeutic positioning.

  • Turkey Tail in Multi-Mushroom Functional Blends

    Rating: good

    Multi-mushroom blends (Host Defense MyCommunity, Real Mushrooms 5 Defenders, Om Mushrooms Master Blend, others) include turkey tail alongside reishi, lion's mane, cordyceps, chaga, others. Modest individual mushroom doses; comprehensive supplementation framework.

  • Paul Stamets Host Defense MyCommunity (Multi-Mushroom Including Turkey Tail)

    Rating: good

    Paul Stamets-developed multi-mushroom blend including turkey tail; substantial brand framework and Stamets advocacy for medicinal mushrooms in cancer adjuvant context. Reasonable framework; substantial brand-specific positioning.

  • Generic "Turkey Tail" Without Standardization

    Rating: caution

    Many products labeled "turkey tail" without specifying fruit body vs mycelium, beta-glucan content, or extraction framework. Substantial commercial opacity; verify specifications before purchase.

Who it works for, and who it does not

  • Cancer adjuvant therapy contexts (oncology coordination)

    Strength of evidence for this group: modest

    Substantial Japanese clinical evidence supports PSK adjunctive use in gastric and colorectal cancer (Nakazato 1994 NEJM 5-year survival improvement in gastric cancer adjuvant; Mitomi 1992 Lancet colorectal). The 2012 NIH-funded Bastyr/UW phase I trial in breast cancer (Torkelson, n=11) provided modest US safety framework. Substantial oncology coordination essential; substantial PSK pharmaceutical positioning in Japan distinct from US supplement-grade framework. Reasonable adjunctive supplementation under oncology coordination; not substitute for established cancer therapy.

  • Adults seeking immune support supplementation

    Strength of evidence for this group: modest

    Substantial beta-glucan immune modulation through PSK and PSP polysaccharide-protein complexes. Modest evidence for natural killer cell activity enhancement and broader immune modulation. Reasonable adjunctive immune supplementation; effect sizes modest in healthy adults.

  • Adults seeking gut microbiome modulation

    Strength of evidence for this group: cautious

    Substantial beta-glucan prebiotic mechanism; modest evidence for gut microbiome composition modulation. Reasonable adjunctive framework for gut health applications; not substitute for dedicated probiotic or prebiotic supplementation.

  • HPV-related cervical lesion adjunctive support

    Strength of evidence for this group: cautious

    Limited but interesting evidence for AHCC (active hexose correlated compound, related polysaccharide framework) in HPV clearance; turkey tail mechanism overlap may provide modest immune-mediated support. Specialist gynecology coordination essential.

  • Adults seeking adaptogenic and longevity supplementation

    Strength of evidence for this group: cautious

    Traditional use frameworks include longevity and vitality applications; modern evidence translation modest. Reasonable adaptogenic supplementation framework.

  • Pregnancy and lactation

    Strength of evidence for this group: cautious

    Limited pregnancy and lactation safety data. Generally cautious supplementation during pregnancy; OB-GYN coordination essential.

  • Anticoagulant users

    Strength of evidence for this group: cautious

    Modest antiplatelet effects through polysaccharide mechanisms; theoretical warfarin and DOAC interaction. Coordinate with anticoagulation management for substantial use.

  • Immunosuppressant users (transplant medicine, autoimmune)

    Strength of evidence for this group: caution

    Beta-glucan immune modulation may substantially interact with immunosuppressant therapy, substantial concern for transplant medicine contexts. Specialist coordination essential; benefit-risk assessment matters.

  • Pediatric use

    Strength of evidence for this group: cautious

    Limited pediatric safety data; specialist coordination if pediatric supplementation considered. Adult formulations not designed for pediatric supplementation.

  • WADA-tested athletes

    Strength of evidence for this group: cautious

    Turkey tail not on WADA prohibited list; contamination concerns affect supplement category broadly. Verify third-party testing for WADA-tested athletes.

Taken with other things

Combinations people actually use. Evidence for one ingredient is not evidence for a pair.

  • Cancer Therapy (Chemotherapy, Radiation)

    Interaction: synergy

    Substantial Japanese clinical evidence supports PSK adjunctive use in gastric and colorectal cancer adjuvant therapy. Substantial oncology coordination essential; turkey tail/PSK as adjunctive support alongside established cancer therapy, not substitute for established treatment.

  • Other Functional Mushrooms (Reishi, Lion's Mane, Cordyceps, Chaga)

    Interaction: synergy

    Reasonable combination for comprehensive functional mushroom supplementation; each mushroom provides distinct pharmacological profile. Multi-mushroom blends provide broader coverage.

  • AHCC (Active Hexose Correlated Compound)

    Interaction: synergy

    Related polysaccharide framework with substantial Japanese clinical evidence including HPV clearance applications. Reasonable mechanism overlap; AHCC has more specific HPV evidence.

  • Probiotic Supplementation

    Interaction: synergy

    Beta-glucan prebiotic mechanism complements probiotic supplementation framework. Reasonable comprehensive gut microbiome support.

  • Immune Support Supplementation (Vitamin D3, Zinc, Vitamin C)

    Interaction: synergy

    Reasonable comprehensive immune support framework; each component provides distinct mechanism profile.

  • Immunosuppressants (Transplant Medicine, Autoimmune)

    Interaction: avoid

    Substantial beta-glucan immune modulation may substantially interact with immunosuppressant therapy, particularly concerning in transplant medicine contexts where immune activation could trigger organ rejection. Specialist coordination essential; generally avoid in active immunosuppression.

  • Anticoagulants (Warfarin, DOACs)

    Interaction: caution

    Modest antiplatelet effects; theoretical warfarin INR interaction. Coordinate with anticoagulation management for substantial use.

  • Pregnancy and Lactation

    Interaction: caution

    Limited safety data; generally avoid during pregnancy. OB-GYN coordination if used.

  • Hypoglycemic Medications

    Interaction: caution

    Modest hypoglycemic activity; theoretical interaction with diabetes medications. Monitor glycemic markers.

  • WADA-Tested Athletes

    Interaction: caution

    Verify third-party testing (NSF Certified for Sport, Informed Sport) for WADA-tested athletes.

What to look for on the label

Look for: cultivated Trametes versicolor fruit body (not mycelium-on-grain); explicit beta-glucan content (30-50% standardized); dual extraction framework (hot water + ethanol) for therapeutic positioning; reputable manufacturer with third-party testing disclosure (heavy metals, contamination, species identity verification); appropriate dose for intended application (1-3g daily standard; 3g daily for cancer adjuvant context under oncology coordination); pharmaceutical PSK or PSP standardization for cancer adjuvant positioning where available. Avoid: products labeled "turkey tail" without species verification (Trametes versicolor confirmed); mycelium-on-grain products with substantial starch content; products without standardized beta-glucan content disclosure; substantial price premium products without corresponding quality verification; cancer adjuvant use without oncology coordination; concurrent use with immunosuppressants without specialist coordination.

Safety in detail

  • Generally very well tolerated; the pharmaceutical-use safety record in Japan since 1977 is extensive.
  • Mild GI upset is the most common side effect at supplement doses.
  • Rare allergic reactions in those with mushroom sensitivities.
  • Theoretical immune-stimulation considerations in autoimmune disease, coordinate with rheumatology.
  • PSK as a pharmaceutical (Japan) and turkey tail as a supplement (US) are not the same product, quality and characterization differ.

What people get wrong

  • Often saidTurkey tail cures cancer.

    ActuallyPSK is an approved adjuvant cancer drug in Japan that improves survival when added to chemotherapy. It is not a stand-alone curative treatment. Use within oncology care, not instead of it.

  • Often saidAny turkey tail supplement is equivalent to PSK.

    ActuallyPharmaceutical PSK is a standardized polysaccharide-protein complex. Supplement-grade products vary substantially; the most rigorous evidence is for pharmaceutical PSK, not unstandardized supplements.

  • Often saidIt's just for cancer patients.

    ActuallyTraditional use is broader. Daily immune support and post-illness recovery are reasonable supplement-grade indications.

Who profits, and who pushes back

  • Western oncology guideline bodies

    Pushes backMajor cancer guideline organizations

    PSK has substantial Japanese clinical evidence but has not been incorporated into Western guidelines. The reasons are complex, heterogeneous trial quality, regulatory differences, and lack of Western replication. The evidence deserves more engagement than it currently receives.

  • Leanna Standish

    Promotes itBastyr University · integrative oncology

    Western integrative oncology researcher who has led US-based clinical trials of turkey tail extract.

  • Paul Stamets

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itHost Defense

    Brand owner. Has personally advocated based on family experience with cancer; financial conflict disclosed.

  • Japanese oncology establishment

    Promotes itNational cancer care

    Treats PSK as a routine adjunct in gastric and colorectal cancer. Decades of clinical experience.

How we got here

Trametes versicolor has long traditional use in TCM (Yunzhi, 云芝) and Japanese kampo (kawaratake). Modern pharmaceutical development began with Kureha's isolation of PSK in 1965. PSK was approved as an adjunct cancer drug in Japan in 1977, making turkey tail one of the few medicinal mushrooms with pharmaceutical-regulatory approval. By the mid-1980s it was among the top-selling cancer pharmaceuticals in Japan.

  1. TraditionalYunzhi (TCM), kawaratake (Japan)
  2. 1965Kureha isolates PSK
  3. 1977PSK approved as cancer adjuvant drug in Japan
  4. 1992Mitomi colorectal cancer adjuvant trial
  5. 1994Nakazato Lancet gastric cancer trial
  6. 2008Standish breast cancer immune-modulation trial
  7. 2014Bao meta-analysis confirms survival improvements

What we do not know

  • Whether US supplement-grade turkey tail products achieve the bioactive content of pharmaceutical PSK.
  • Whether the Japanese cancer-adjuvant evidence generalizes to Western oncology practice and demographic populations.
  • Whether daily-immune supplement-dose use (1-3g/day) in non-cancer populations produces meaningful clinical benefit.
  • Why Western cancer guidelines have not incorporated the substantial Japanese pharmaceutical-grade evidence.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Pharmaceutical PSK (Krestin) is available only in Japan and a few other Asian markets through medical channels. US dietary supplement products vary widely in standardization. Look for products that specify PSK and PSP content; fruiting body extract is the studied form; mycelium-on-grain lacks the pharmaceutical-grade bioactive content. Real Mushrooms, Host Defense, and a small number of others publish polysaccharide quantification.

At a glance

Active fractions
PSK (Krestin), PSP (Polysaccharopeptide)
Pharmaceutical status
Approved drug in Japan since 1977
US status
Dietary supplement only
Typical supplement dose
1-3g/day extract
Pharmaceutical PSK dose
3g/day adjunct to chemotherapy
Indication
Gastric, colorectal cancer adjuvant (Japan)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Turkey Tail. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies that matter

  • Nakazato gastric cancer trial1994

    Lancet publication: PSK added to 5-FU-based chemotherapy improved 5-year survival in gastric cancer. One of the foundational pharmaceutical-grade trials.

  • Mitomi colorectal cancer trial1992

    PSK improved disease-free survival when added to chemotherapy in stage III colorectal cancer.

  • Bao oral PSK gastric cancer meta-analysis2014

    Meta-analysis of multiple Japanese PSK trials confirming improvements in 1-year, 3-year, and 5-year survival.

  • Standish Bastyr immune-modulation trial2008

    PSK in women with breast cancer after standard treatment improved natural killer cell activity and lymphocyte subset profiles.